HosseinBorghaeiDO

Oncology • Philadelphia, PA

Hematologic Oncology, Thoracic Cancer

Director, Thoracic Medical Oncology

Join to view full profile

Dr. Borghaei is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Borghaei's full profile

Already have an account?

Office
333 Cottman Ave
Philadelphia, PA 19111
Phone+1 215-214-4297

Fax+1 215-728-3639
Is this information wrong?

Summary

Dr. Hossein Borghaei is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Temple University Hospital and Fox Chase Cancer Center-American Oncologic Hospital. He received his medical degree from Philadelphia College of Osteopathic Medicine and has been in practice 21 years. He specializes in hematologic oncology and thoracic cancer and is experienced in immunotherapy, non-small cell lung cancer, urologic oncology, biomedical research, and combined modality therapy.

Education & Training

Temple University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
Graduate HospitalResidency, Internal Medicine, 1997 - 2000
Philadelphia College of Osteopathic MedicineClass of 1996

Certifications & Licensure

PA State License 1997 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2007 Jul 05
Completed
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer Start of enrollment: 2011 Oct 20
Terminated
Phase 1, Phase 2
Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) Start of enrollment: 2012 Dec 11
Completed
Phase 2
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors Start of enrollment: 2012 Jun 28
Completed
Phase 1
Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer Start of enrollment: 2012 Aug 23
Completed
Not Applicable
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Completed
Phase 3
Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Start of enrollment: 2015 Mar 01
Terminated
Not Applicable
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer Start of enrollment: 2017 Mar 29
Terminated
Phase 1, Phase 2
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC Start of enrollment: 2020 Oct 08
Recruiting
Phase 2
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC Start of enrollment: 2022 Jul 13
Withdrawn
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.
Joel W Neal, Katherine Minichiello, Ryan Brennick, Richard S P Huang, Matthew C Hiemenz, Cornel Amler, Jyoti Patel, Karen L Reckamp, Louise Highleyman, Mary W Redman, ...> ;The Oncologist. 2024 Apr 10
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers.
Maishara Muquith, Magdalena Espinoza, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry, Emmanuel S Antonarakis, Stephanie L Graff, Michael J Hall, Hossein Bo...> ;Nature Cancer. 2024 Mar 25
Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
Lova Sun, Elizabeth A Handorf, Yunyun Zhou, Hossein Borghaei, Charu Aggarwal, Jessica Bauman> ;Lung Cancer. 2024 Apr 1
Influence ofComutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in-Mutant Non-Small-Cell Lung Cancer.
Naqash, A., Floudas, C., Aber, E., Maoz, A., Nassar, A., Adib, E., Choucair, K., Xiu, J., Baca, Y., Ricciuti, B., Alessi, J., Awad, M., Kim, C., Judd, J., Raez, L., Lo...> ;JCO Precision Oncology. 2024 Feb 1
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Pa...
Beckermann, K., El Osta, B., Sanborn, R., Selvaggi, G., Whisenant, J., Heimann-Nichols, E., Berry, L., Hsu, C., Shyr, Y., Horn, L., Bestvina, C., Borghaei, H., Lammers...> ;JTO Clinical and Research Reports. 2024 Feb 1
Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
David E Gerber, Yating Wang, Suresh S Ramalingam, Sheena Bhalla, Zhuoxin Sun, Hossein Borghaei, Julie R Brahmer, Joan H Schiller> ;The Oncologist. 2024 Apr 4
Validation of a Molecular Diagnostic Test for Circulating Tumor DNA by Next-Gen Sequencing.
Sandra V Fernandez, Yin Fei Tan, Shilpa Rao, Patricia Fittipaldi, Fathima Sheriff, Hossein Borghaei, Efrat Dotan, Jennifer S Winn, Martin J Edelman, Joseph Treat, Juli...> ;International Journal of Molecular Sciences. 2023 Oct 30
1 citations
How to Treat-Mutated Non-Small Cell Lung Cancer.
Neel Belani, Katherine Liang, Michael Fradley, Julia Judd, Hossein Borghaei> ;JACC. Cardiooncology. 2023 Aug 1
2 citations
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.
Matthew Zibelman, Alexander W MacFarlane 4th, Kimberly Costello, Thomas McGowan, John O'Neill, Rutika Kokate, Hossein Borghaei, Crystal S Denlinger, Efrat Dotan, Danie...> ;Nature Communications. 2023 Jul 27
Novel Immunotherapeutics: Perspectives on Checkpoints, Bispecifics, and Vaccines in Development.
Firas Y Kreidieh, Hussein A Tawbi, Aikaterini Alexaki, Hossein Borghaei, Lana E Kandalaft> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2023 Jun 1
3 citations
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer WithMutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study.
Apar K Ganti, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Elie G Dib, Herbert L Duvivier, Eugene R Ahn, Deepti Behl, Hossein Borghaei, Ani S Balmanoukian, An...> ;JCO Precision Oncology. 2023 Jun 1
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Har...
J Nicholas Bodor, Jyoti D Patel, Heather A Wakelee, Benjamin P Levy, Hossein Borghaei, Bruna Pellini, Michael R Costello, Jonathan E Dowell, Gene Finley, Chao H Huang,...> ;Clinical Lung Cancer. 2023 Nov 1
10 citations
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Michael Schenker, Bogdan Zurawski, Sang-We Kim, Mauricio Mahave, Aurelia Alexandru, Solange Peters, Adam Pluzanski, ...> ;Journal of Thoracic Oncology. 2023 Aug 1
36 citations
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Luis Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa L Johnson, Neeltje St...> ;Journal of Clinical Oncology. 2023 Jun 1
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer.
Robert Hsu, Denaly Chen, Bing Xia, Rebecca Feldman, Wendy Cozen, Luis E Raez, Hossein Borghaei, Chul Kim, Misako Nagasaka, Hirva Mamdani, Ari M Vanderwalde, Gilberto L...> ;Frontiers in Oncology. 2023 Jan 1
3 citations
family fusions are recurrent and actionable oncogenic targets across cancer types.
Laura Schubert, Andrew Elliott, Anh T Le, Adriana Estrada-Bernal, Robert C Doebele, Emil Lou, Hossein Borghaei, Michael J Demeure, Razelle Kurzrock, Joshua E Reuss, Sa...> ;Frontiers in Oncology. 2023 Jan 1
2 citations
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management.
Houssein Safa, Fawzi Abu Rous, Neel Belani, Hossein Borghaei, Shirish Gadgeel, Balazs Halmos> ;Targeted Oncology. 2023 Jan 1
8 citations
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
H Borghaei, T-E Ciuleanu, J-S Lee, A Pluzanski, R Bernabe Caro, M Gutierrez, Y Ohe, M Nishio, J Goldman, N Ready, D R Spigel, S S Ramalingam, L G Paz-Ares, J F Gainor,...> ;Annals of Oncology. 2023 Feb 1
Advances in immune checkpoint inhibition for patients with lung cancer.
Hossein Borghaei> ;Clinical Advances in Hematology & Oncology. 2022 Nov 1
59 citations
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Ad...> ;Journal of Clinical Oncology. 2023 Feb 20
9 citations
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
Luis G Paz-Ares, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong-Seok Lee, Justin F Gainor, Gregory A Otterson, Clarisse Audigier-Valette, Neal Ready, Michael Schenker, He...> ;Journal of Thoracic Oncology. 2023 Jan 1
12 citations
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of ...
Alessio Cortellini, Biagio Ricciuti, Hossein Borghaei, Abdul Rafeh Naqash, Antonio D'Alessio, Claudia A M Fulgenzi, Alfredo Addeo, Giuseppe L Banna, David James Pinato> ;Cancer. 2022 Aug 15
3 citations
Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians.
Gerard J Criner, Alvar Agusti, Hossein Borghaei, Joseph Friedberg, Fernando J Martinez, Curtis Miyamoto, Claus F Vogelmeier, Bartolome R Celli> ;Chronic Obstructive Pulmonary Diseases. 2022 Jul 29
50 citations
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Patrick M. Forde, Valsamo Anagnostou, Z. Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z. Dudek, Hossein...> ;Nature Medicine. 2021 Nov 8
13 citations
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
Misako Nagasaka, Vijendra Singh, Yasmine Baca, Ammar Sukari, Chul Kim, Hirva Mamdani, Alexander I. Spira, Dipesh Uprety, Gerold Bepler, Edward S. Kim, Luis E. Raez, Sa...> ;Clinical Lung Cancer. 2021 Oct 18
Join now to see all

Press Mentions

Pleural, Pericardial Effusion cfDNA Detects Actionable EGFR MutationsJanuary 19th, 2023
Long-Term Benefits of Nivolumab in Pre-Treated NSCLCJune 25th, 2021
Survival Benefit with Nivolumab Extends to 5 Years in NSCLCApril 26th, 2021
Join now to see all